Ritalin (methylphenidate)
Description
Stimulant for ADHD — appetite suppression and insomnia; controlled prescription.
Stimulant or non-stimulant focus medication — appetite and sleep effects.
SA brand & generic formulations
Registered trade names commonly seen on South African scripts for methylphenidate.†
| Brand / label | Generic | Formulation | Type | |
|---|---|---|---|---|
| Ritalin (methylphenidate) This page | methylphenidate | IR tablet | ADHD | |
| Ritalin LA (methylphenidate LA) | methylphenidate | LA capsule | ADHD | → |
| Concerta (methylphenidate ER) | methylphenidate | OROS ER | ADHD | → |
| Medikinet LA (methylphenidate LA) | methylphenidate | LA capsule | ADHD | → |
| Rubifen (methylphenidate) | methylphenidate | IR tablet | ADHD | → |
| Attenta (methylphenidate) | methylphenidate | IR tablet | ADHD | → |
Methylphenidate comes in three SA formulation families: immediate-release (IR) tablets for short coverage; long-acting (LA) capsules with beaded release; and osmotic extended-release (Concerta OROS) for sustained daytime effect. Insurers and employers may query appetite, sleep, and afternoon crash patterns — record the exact brand, strength, and dosing time on your script. †
Strengths available in SA
- 5 mg tablet
- 10 mg tablet
- 20 mg tablet
- 10 mg LA capsule
- 20 mg LA capsule
- 30 mg LA capsule
- 40 mg LA capsule
- 18 mg ER tablet
- 27 mg ER tablet
- 36 mg ER tablet
- 54 mg ER tablet
Strengths collated from SA package inserts and intake presets — confirm against dispensed pack.†
Typical SA dosing & schedules
IR (Ritalin/Rubifen/Attenta): 5–20 mg mane and/or lunchtime titrated; LA (Ritalin LA/Medikinet LA): 10–40 mg mane; OROS ER (Concerta): 18–54 mg mane per response.
General range for claims context — must match your script.†
Dose frequency options
- Once daily
- Twice daily (BD)
- Three times daily (TDS)
- Four times daily
- Each morning (mane)
- At night (nocte)
- As needed (PRN)
- Once weekly
- Fortnightly
- Monthly
- Per session / appointment
- Other schedule
Related conditions
Hover for a brief clinical summary · click to open the condition page with linked medications.
↔ Illnesses & injuries — condition↔medication cross-links on each detail page
References & footnotes
- Brand–generic pairings reflect products commonly encountered in SA scripts; confirm current SAHPRA registration on the label or package insert. SAHPRA; MIMS / SA package inserts
- Strength list shows unit doses commonly available in SA tablets, capsules, inhalers, or injections — verify against the dispensed product. MIMS / SA package inserts; SA Essential Medicines List (EML); ClaimBuddy curated
- Typical dosing is a general SA prescribing range for claims context only — actual dose must match the treating clinician's script. MIMS / SA package inserts; ClaimBuddy curated
- IR, LA, and ER methylphenidate formulations differ in onset, duration, and titration — document the exact brand and strength on your script for claims evidence. SAHPRA; MIMS / SA package inserts; ClaimBuddy curated
Where this data comes from
ClaimBuddy collates SA-market brand names and strengths for intake — always verify against your script and clinician.
- WHO ICD-10 — Condition names and ICD-10-CM codes in the condition index.
- SAHPRA — South African medicine registration context; brand products must be SAHPRA-registered to be dispensed.
- MIMS / SA package inserts — Registered strengths, formulations, and typical dosing ranges for SA market products.
- SA Essential Medicines List (EML) — Public-sector formulary context for commonly available strengths.
- ClaimBuddy curated — SA brand name collation from intake presets, claim-frequency mapping, and work-impact notes — not a substitute for prescribing information.